
This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

August 22nd 2017